## **Curtis R Pickering**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6196393/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy. Frontiers in Immunology, 2022, 13, 840923.	4.8	13
2	p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade. Cancer Research, 2022, 82, 916-928.	0.9	13
3	Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clinical Cancer Research, 2022, , .	7.0	3
4	Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Advances in Radiation Oncology, 2022, 7, 100989.	1.2	1
5	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia, 2022, 31, 100813.	5.3	14
6	Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. International Journal of Radiation Biology, 2021, 97, 1121-1128.	1.8	30
7	The mutational landscape of early―and typicalâ€onset oral tongue squamous cell carcinoma. Cancer, 2021, 127, 544-553.	4.1	27
8	Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2021, 27, 2560-2570.	7.0	37
9	Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis. , 2021, 9, e001955.		28
10	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. Journal of Thoracic Oncology, 2021, 16, 1821-1839.	1.1	34
11	Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma. Life Sciences, 2021, 278, 119541.	4.3	9
12	Biology of the Radio- and Chemo-Responsiveness in HPV Malignancies. Seminars in Radiation Oncology, 2021, 31, 274-285.	2.2	13
13	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nature Communications, 2021, 12, 6340.	12.8	17
14	Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. Journal of the National Cancer Institute, 2020, 112, 266-277.	6.3	5
15	Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma. Cancer, 2020, 126, 4498-4510.	4.1	6
16	Identifying predictors of <scp>HPV</scp> â€related head and neck squamous cell carcinoma progression and survival through patientâ€derived models. International Journal of Cancer, 2020, 147, 3236-3249.	5.1	40
17	Loss of p53 drives neuron reprogramming in head and neck cancer. Nature, 2020, 578, 449-454.	27.8	241
18	Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic–induced necroptosis. JCI Insight, 2020, 5, .	5.0	28

CURTIS R PICKERING

#	Article	IF	CITATIONS
19	Tumor immune microenvironment alterations in penile squamous cell carcinoma using multiplex immunofluorescence and image analysis approaches Journal of Clinical Oncology, 2020, 38, 4-4.	1.6	6
20	p16INK4a expression and survival outcomes in patients with penile squamous cell carcinoma: The M.D. Anderson Cancer Center Experience Journal of Clinical Oncology, 2020, 38, 5-5.	1.6	2
21	Association of radiation treatment failure in head and neck cancer with differential immune infiltrate Journal of Clinical Oncology, 2020, 38, 6558-6558.	1.6	Ο
22	PDK1 Mediates <i>NOTCH1</i> -Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition. Clinical Cancer Research, 2019, 25, 3329-3340.	7.0	36
23	Genetics and penile cancer. Current Opinion in Urology, 2019, 29, 364-370.	1.8	26
24	Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clinical Cancer Research, 2019, 25, 1441-1442.	7.0	6
25	Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight, 2019, 4, .	5.0	67
26	Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors Journal of Clinical Oncology, 2019, 37, 505-505.	1.6	12
27	Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234 Journal of Clinical Oncology, 2019, 37, 6010-6010.	1.6	2
28	Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection Journal of Clinical Oncology, 2019, 37, 6067-6067.	1.6	0
29	Identifying adverse molecular features of HPV+ head and neck cancers using patient-derived models Journal of Clinical Oncology, 2019, 37, 6057-6057.	1.6	0
30	Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay. Translational Oncology, 2018, 11, 477-486.	3.7	11
31	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
32	High-Risk <i>TP53</i> Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma. Clinical Cancer Research, 2018, 24, 1727-1733.	7.0	36
33	Distinct pattern of <i>TP53</i> mutations in human immunodeficiency virus–related head and neck squamous cell carcinoma. Cancer, 2018, 124, 84-94.	4.1	22
34	<i>CDKN2A/p16</i> Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Research, 2018, 78, 781-797.	0.9	37
35	Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10666-10671.	7.1	33
36	Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Letters, 2018, 431, 64-72.	7.2	25

CURTIS R PICKERING

#	Article	IF	CITATIONS
37	Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma. BMC Cancer, 2018, 18, 758.	2.6	16
38	Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Letters, 2017, 392, 71-82.	7.2	22
39	Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. Head and Neck, 2017, 39, 1131-1137.	2.0	40
40	Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 2713-2722.	7.0	91
41	APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nature Communications, 2017, 8, 465.	12.8	89
42	Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk <i>TP53</i> Mutation. Clinical Cancer Research, 2017, 23, 6541-6554.	7.0	27
43	Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget, 2017, 8, 86369-86383.	1.8	50
44	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clinical Cancer Research, 2016, 22, 4643-4650.	7.0	64
45	Mechanisms for the Generation of Two Quadruplications Associated with Split-Hand Malformation. Human Mutation, 2016, 37, 160-164.	2.5	16
46	Evolutionary Action Score of <i>TP53</i> Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Research, 2015, 75, 1205-1215.	0.9	78
47	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Science Translational Medicine, 2015, 7, 293ra104.	12.4	372
48	Evolutionary Action Score of <i>TP53</i> Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Research, 2015, 75, 1527-1536.	0.9	139
49	New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development. Cancer Prevention Research, 2015, 8, 1027-1035.	1.5	60
50	How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. Cancer, 2015, 121, 806-816.	4.1	13
51	Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. Clinical Cancer Research, 2014, 20, 6582-6592.	7.0	493
52	Sequencing HNC: Emergence of Notch Signaling. , 2014, , 303-323.		0
53	Key tumor suppressor genes inactivated by "greater promoter―methylation and somatic mutations in head and neck cancer. Epigenetics, 2014, 9, 1031-1046.	2.7	122
54	HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head and Neck, 2014, 36, 1547-1554.	2.0	31

CURTIS R PICKERING

#	Article	IF	CITATIONS
55	Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers. Clinical Cancer Research, 2014, 20, 3842-3848.	7.0	124
56	High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer, 2013, 119, 3034-3042.	4.1	180
57	Lessons learned from nextâ€generation sequencing in head and neck cancer. Head and Neck, 2013, 35, 454-463.	2.0	58
58	Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53. Molecular Cancer Therapeutics, 2013, 12, 1860-1873.	4.1	108
59	Bcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients. Cancer Discovery, 2013, 3, 258-259.	9.4	2
60	Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers. Cancer Discovery, 2013, 3, 770-781.	9.4	484
61	Coordinated Targeting of the EGFR Signaling Axis by MicroRNA-27a*. Oncotarget, 2013, 4, 1388-1398.	1.8	44
62	Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on <i>TP53</i> mutational status. Cancer, 2012, 118, 711-721.	4.1	50
63	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i> . Science, 2011, 333, 1154-1157.	12.6	1,568
64	Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer, 2011, 117, 2926-2938.	4.1	112
65	Disruptive <i>TP53</i> Mutation Is Associated with Aggressive Disease Characteristics in an Orthotopic Murine Model of Oral Tongue Cancer. Clinical Cancer Research, 2011, 17, 6658-6670.	7.0	94
66	Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites. Clinical Cancer Research, 2011, 17, 7248-7264.	7.0	230
67	Unique training brings young scientists up to speed in translational research. DMM Disease Models and Mechanisms, 2009, 2, 211-211.	2.4	0
68	p16INK4a Modulates p53 in Primary Human Mammary Epithelial Cells. Cancer Research, 2006, 66, 10325-10331.	0.9	53
69	p38 Regulates Cyclooxygenase-2 in Human Mammary Epithelial Cells and Is Activated in Premalignant Tissue. Cancer Research, 2005, 65, 1792-1799.	0.9	53